BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28150872)

  • 1. Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.
    Poi MJ; Li J; Sborov DW; VanGundy Z; Cho YK; Lamprecht M; Pichiorri F; Phelps MA; Hofmeister CC
    Mol Carcinog; 2017 Jul; 56(7):1722-1732. PubMed ID: 28150872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of
    Li J; Seligson N; Zhang X; Johnson J; Vangundy Z; Wang D; Phelps M; Hofmeister C; Sadee W; Poi MJ
    Anticancer Res; 2020 Oct; 40(10):5707-5713. PubMed ID: 32988896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
    Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
    J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk.
    Burd CE; Jeck WR; Liu Y; Sanoff HK; Wang Z; Sharpless NE
    PLoS Genet; 2010 Dec; 6(12):e1001233. PubMed ID: 21151960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of LncRNA ANRIL mediated by miR-411-3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1α.
    Wang M; Zhao HY; Zhang JL; Wan DM; Li YM; Jiang ZX
    Exp Cell Res; 2020 Nov; 396(1):112280. PubMed ID: 32961145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
    Nath CE; Trotman J; Tiley C; Presgrave P; Joshua D; Kerridge I; Kwan YL; Gurney H; McLachlan AJ; Earl JW; Nivison-Smith I; Zeng L; Shaw PJ
    Br J Clin Pharmacol; 2016 Jul; 82(1):149-59. PubMed ID: 26879446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single Nucleotide Polymorphism (SNP) in the
    Li J; Persaud AK; Johnson JA; Sborov DW; Phelps MA; Hofmeister CC; Poi MJ
    Anticancer Res; 2022 Jan; 42(1):385-395. PubMed ID: 34969749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients.
    Thyagarajan B; Arora M; Guan W; Barcelo H; Jackson S; Kumar S; Gertz M
    Leuk Res; 2013 Nov; 37(11):1527-31. PubMed ID: 24129343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
    Persaud AK; Li J; Johnson JA; Seligson N; Sborov DW; Duah E; Cho YK; Wang D; Phelps MA; Hofmeister CC; Poi MJ
    Mol Carcinog; 2019 Dec; 58(12):2327-2339. PubMed ID: 31544312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
    N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B.
    Congrains A; Kamide K; Oguro R; Yasuda O; Miyata K; Yamamoto E; Kawai T; Kusunoki H; Yamamoto H; Takeya Y; Yamamoto K; Onishi M; Sugimoto K; Katsuya T; Awata N; Ikebe K; Gondo Y; Oike Y; Ohishi M; Rakugi H
    Atherosclerosis; 2012 Feb; 220(2):449-55. PubMed ID: 22178423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA ANRIL promotes the invasion and metastasis of thyroid cancer cells through TGF-β/Smad signaling pathway.
    Zhao JJ; Hao S; Wang LL; Hu CY; Zhang S; Guo LJ; Zhang G; Gao B; Jiang Y; Tian WG; Luo DL
    Oncotarget; 2016 Sep; 7(36):57903-57918. PubMed ID: 27507052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplants for multiple myeloma.
    Tricot G; Jagannath S; Vesole DH; Bracy D; Desikan KR; Siegel D; Barlogie B
    Leuk Lymphoma; 1996 Jun; 22(1-2):25-36. PubMed ID: 8724525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
    Giglia JL; White MJ; Hart AJ; Toro JJ; Freytes CO; Holt CC; Cai Y; Williams SM; Brandt SJ
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):1014-20. PubMed ID: 24704384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ANRIL inhibits p15(INK4b) through the TGFβ1 signaling pathway in human esophageal squamous cell carcinoma.
    Chen D; Zhang Z; Mao C; Zhou Y; Yu L; Yin Y; Wu S; Mou X; Zhu Y
    Cell Immunol; 2014; 289(1-2):91-6. PubMed ID: 24747824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Single Nucleotide Polymorphism in
    Poi MJ; Li J; Johnson JA; Cho YK; Sborov DW; Phelps MA; Hofmeister CC
    Anticancer Res; 2019 Jan; 39(1):67-72. PubMed ID: 30591441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.
    Gebauer N; Biersack H; Czerwinska AC; Schemme J; Hardel TT; Bernard V; Rades D; Lehnert H; Luley KB; Thorns C
    Leuk Lymphoma; 2016; 57(6):1482-6. PubMed ID: 26414189
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
    Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H
    BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.